GLOCER THOMAS H 4

What Happened
Thomas H. Glocer, a director of Merck & Co., received a grant of 1,853.1 phantom stock units on May 29, 2026. The units were valued at $118.72 each, for a total reported value of $220,000. This is an award (not an open-market purchase or sale) reported as a derivative grant.

Key Details

• Transaction type: Award/Grant of derivative units (code A).
• Date and valuation: 2026-05-29; 1,853.1 units at $118.72 each = $220,000.
• Settlement: Footnote F2 indicates these phantom stock units are to be settled 100% in cash upon the reporting person's termination of service, according to the Plan for Deferred Payment of Directors' Compensation.
• Conversion: Footnote F1 indicates a 1-for-1 conversion (each unit equals one share for purposes of the grant).
• Holdings note: Footnote F3 says reported holdings include shares from dividend reinvestment transactions. The filing does not state total shares owned after this grant.
• Filing timeliness: Report filed 2026-06-02 for a 2026-05-29 transaction — within the usual two-business-day Form 4 reporting window.

Context
This was a routine director compensation award (phantom stock units settled in cash upon termination) rather than a market purchase or sale. Such grants are standard for board members and do not necessarily signal the insider buying or selling stock in the open market.